Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Imeglimin may prolong erythrocyte lifespan, affecting HbA1c levels.
Last updated August 15, 2026
Key finding
The change in hemoglobin concentration at 6 months was not statistically significant (mean ± SD: −0.2 ± 0.9 g/dL; p = 0.23).
Imeglimin 2,000 mg/day for six months in adults with type 2 diabetes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Imeglimin 2,000 mg/day for six months in adults with type 2 diabetes.
Clinical relevance
This study evaluated Imeglimin 2,000 mg/day for six months in adults with type 2 diabetes.
Keep in mind
Limitations were not clearly described in the extracted text.
Published in
Journal Reference
Publication details and source links for this paper.
Takeshi O, Shinichiro S, Miyoko S, et al. Exploratory Clinical Trial Evaluating the Effects of Imeglimin on Erythrocyte Lifespan and Glycemic Markers in Patients with Type 2 Diabetes. Frontiers in Endocrinology. 2025;16:1699591. doi:10.3389/fendo.2025.1699591
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Imeglimin and 1,5-Anhydroglucitol, Change in erythrocyte lifespan during treatment, Change in glycoalbumin from baseline, and 2 more.
This study contributes evidence to
Primary intervention
Imeglimin
Primary outcomes
- 1,5-Anhydroglucitol
- Change in erythrocyte lifespan during treatment
- Change in glycoalbumin from baseline
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
2
Related topics
5
Evidence pairs
880
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
Fasting Blood Glucose
matched_outcome
Related evidence
Evidence topic
HbA1c Reduction
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Change in erythrocyte lifespan during treatment
Imeglimin → Change in erythrocyte lifespan during treatment
Imeglimin → Change in erythrocyte lifespan during treatment
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerChange in glycoalbumin from baseline
Imeglimin → Change in glycoalbumin from baseline
Imeglimin → Change in glycoalbumin from baseline
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Imeglimin and HbA1c, Imeglimin and Change in glycoalbumin from baseline.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Imeglimin → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
3 studies
outcome_hubMeasures HbA1c as a key outcome.
Imeglimin Evidence Hub
All studies on Imeglimin
3 studies
intervention_hubContributes to Imeglimin evidence base.
Change in glycoalbumin from baseline Evidence Hub
All studies measuring Change in glycoalbumin from baseline
2 studies
outcome_hubMeasures Change in glycoalbumin from baseline as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Imeglimin and HbA1c
Intervention: ImegliminOutcome: HbA1c
3 results
All studies on Imeglimin and Change in glycoalbumin from baseline
Intervention: ImegliminOutcome: Change in glycoalbumin from baseline
2 results
All studies on Imeglimin
Intervention: Imeglimin
3 results
All studies measuring HbA1c
Outcome: HbA1c
3 results
All studies measuring Change in glycoalbumin from baseline
Outcome: Change in glycoalbumin from baseline
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Imeglimin lower HbA1c?
Strong Evidence
Imeglimin appears to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Imeglimin improve change in glycoalbumin from baseline?
Moderate Evidence
Imeglimin appears to improve change in glycoalbumin from baseline.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Change in glycoalbumin from baseline
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Imeglimin improve 1,5-anhydroglucitol?
Emerging Evidence
Imeglimin appears to improve 1,5-anhydroglucitol.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
1,5-Anhydroglucitol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Imeglimin improve change in erythrocyte lifespan during treatment?
Emerging Evidence
Imeglimin appears to improve change in erythrocyte lifespan during treatment.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Change in erythrocyte lifespan during treatment
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Imeglimin enhances insulin secretion in type 2 diabetes treatmentHRS-7535 improves glycemic control in adults with type 2 diabetesImeglimin improves glycaemic control in type 2 diabetes patientsAdding medications improves blood sugar control in diabetes patients.Bariatric surgery improves glucose homeostasis in type 2 diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.